Prana’s PBT434 Inhibits Accumulation of Parkinson’s Protein and Subsequent Death of Brain Cells.

[Marketwired] – Prana Biotechnology today announced that PBT434, Prana’s lead drug candidate for Parkinson’s Disease and movement disorders, will be presented at two international conferences in March. The key finding … more

View todays social media effects on PRAN

View the latest stocks trending across Twitter. Click to view dashboard

See who Prana is hiring next, click here to view